Metformin remains the most common first-line medication for type 2 diabetes, and for most people without heart, kidney, or vascular complications, it’s still where treatment begins. But “best” depends heavily on your individual health profile. Newer drug classes, particularly GLP-1 receptor agonists and SGLT2 inhibitors, have changed the landscape dramatically, offering not just blood sugar control but meaningful protection for the heart and kidneys. The right medication for you depends on your A1C level, your weight goals, your risk of complications, and how your body tolerates treatment.
Why Metformin Is Still the Starting Point
Metformin has been the default first-line treatment for type 2 diabetes for decades, and the 2025 American Diabetes Association guidelines still position it as a commonly used initial therapy for people who need glucose lowering without other complicating health factors. It works primarily by reducing the amount of sugar your liver releases into your bloodstream. It also improves how sensitive your cells are to insulin and appears to act on the gut in ways researchers are still uncovering, including influencing gut hormones and the microbiome.
Metformin typically lowers A1C by about 1 to 1.5 percentage points, is inexpensive, widely available as a generic, and doesn’t cause weight gain. It also carries no risk of causing low blood sugar on its own. The main downside is gastrointestinal trouble: nausea, diarrhea, and stomach discomfort are common early on, though extended-release versions and gradual dose increases help most people adjust. For someone newly diagnosed with moderately elevated blood sugar and no major cardiovascular or kidney concerns, metformin is a solid, well-proven choice.
GLP-1 Receptor Agonists: Strong on Weight and Heart Protection
GLP-1 receptor agonists (sometimes called GLP-1 RAs) work by mimicking a gut hormone that signals your pancreas to release insulin when blood sugar rises, slows digestion, and reduces appetite. The result is meaningful blood sugar reduction paired with significant weight loss, which makes this class especially valuable for people with type 2 diabetes who are also carrying excess weight. Common medications in this class include semaglutide (Ozempic, Rybelsus) and dulaglutide (Trulicity), available as weekly injections or, in some cases, daily pills.
Beyond glucose control, GLP-1 RAs have proven cardiovascular benefits. Clinical trials show they reduce the risk of major cardiovascular events, with a particularly strong effect on stroke prevention. Several stroke and cardiovascular guidelines now recommend them for people with type 2 diabetes who have established heart disease or high cardiovascular risk. Nausea is the most frequently reported side effect, especially during the first weeks of treatment, and tends to fade as the body adjusts. Starting at a low dose and increasing gradually is standard practice to minimize this.
SGLT2 Inhibitors: Best for Heart Failure and Kidney Disease
SGLT2 inhibitors take a completely different approach. They block a protein in your kidneys that normally reabsorbs sugar back into your blood, causing excess glucose to leave through your urine instead. This mechanism lowers blood sugar without relying on insulin at all, which means the risk of low blood sugar is minimal. Common medications include empagliflozin (Jardiance) and dapagliflozin (Farxiga).
Where SGLT2 inhibitors really stand out is in protecting the heart and kidneys. They significantly reduce the risk of hospitalization for heart failure, so much so that European cardiology guidelines now list them as a core treatment for heart failure regardless of diabetes status. They also slow the progression of chronic kidney disease. On top of that, they produce a mild diuretic effect that lowers systolic blood pressure by roughly 2 to 10 mmHg and reduces uric acid levels, which is beneficial since elevated uric acid is an independent risk factor for kidney and cardiovascular disease.
Current guidelines are clear: if you have documented heart failure or chronic kidney disease, SGLT2 inhibitors should be part of your treatment, often as a first-line addition regardless of your current A1C. For people with established cardiovascular disease but without heart failure specifically, either SGLT2 inhibitors or GLP-1 RAs are appropriate.
DPP-4 Inhibitors: A Gentler Option
DPP-4 inhibitors (sitagliptin, linagliptin, and others) work by blocking an enzyme that breaks down your body’s natural GLP-1, so more of this blood-sugar-lowering hormone stays active after meals. They produce a moderate A1C reduction of about 0.5 to 0.8 percentage points, which is less than what you’d get from metformin, GLP-1 RAs, or SGLT2 inhibitors.
Their appeal is tolerability. DPP-4 inhibitors are weight neutral, meaning they don’t cause weight gain or loss. They carry very low risk of hypoglycemia. Large trials involving nearly 50,000 patients confirmed they don’t increase cardiovascular risk, though unlike GLP-1 RAs and SGLT2 inhibitors, they don’t provide cardiovascular benefit either. DPP-4 inhibitors are a reasonable add-on for people who need modest additional glucose lowering, can’t tolerate more potent options, or want an oral medication with minimal side effects.
Sulfonylureas: Effective but Riskier
Sulfonylureas (glipizide, glimepiride, glyburide) are among the oldest diabetes medications still in use. They stimulate your pancreas to produce more insulin, which effectively lowers blood sugar but comes with two significant trade-offs: they cause weight gain, and they carry a real risk of hypoglycemia, or dangerously low blood sugar. Head-to-head trials show that DPP-4 inhibitors cause roughly 76% fewer episodes of low blood sugar compared to sulfonylureas.
Sulfonylureas are inexpensive and available everywhere, which keeps them relevant in settings where cost is the primary barrier to treatment. But for most people who have access to newer options, the risks of hypoglycemia and weight gain make sulfonylureas a less attractive long-term choice.
When You Might Need Two Medications Right Away
Not everyone starts with a single drug. If your A1C is 1.5 to 2 percentage points above your target at diagnosis (typically above 8.5 to 9%), guidelines from the American Diabetes Association, the American Association of Clinical Endocrinology, and the Korean Diabetes Association all recommend starting two medications simultaneously. The logic is straightforward: a single drug is unlikely to bring blood sugar into range from that high a starting point, and waiting months to confirm that just delays effective treatment.
If your A1C is above 9% or more than 1.5 points above target, triple combination therapy may be considered from the outset. The specific combinations depend on your other health conditions, but a common pairing is metformin with either a GLP-1 RA or an SGLT2 inhibitor, which addresses blood sugar from two different directions while also offering cardiovascular or kidney protection.
How Your Health Profile Shapes the Choice
The 2025 ADA guidelines emphasize a person-centered approach, meaning the “best” medication depends on factors specific to you: your A1C goal, your risk of low blood sugar, your weight, your cardiovascular history, your kidney function, and even your preferences about injections versus pills. Here’s how the major classes line up across common priorities:
- Heart failure or chronic kidney disease: SGLT2 inhibitors are first choice, added to (or even instead of) metformin regardless of A1C level.
- Established cardiovascular disease or stroke risk: GLP-1 RAs and SGLT2 inhibitors are both appropriate. GLP-1 RAs have a stronger track record for stroke prevention specifically.
- Weight loss is a priority: GLP-1 RAs produce the most significant weight reduction of any diabetes drug class.
- Avoiding low blood sugar is critical: Metformin, SGLT2 inhibitors, GLP-1 RAs, and DPP-4 inhibitors all carry minimal hypoglycemia risk. Sulfonylureas are the main class to watch for.
- Cost is the primary concern: Metformin and sulfonylureas are the least expensive options by a wide margin. Generic SGLT2 inhibitors are becoming available in some markets.
- Tolerability matters most: DPP-4 inhibitors have the mildest side effect profile overall.
There is no single best diabetes medication for everyone. But the landscape has shifted meaningfully in recent years. For a growing number of people, particularly those with any cardiovascular or kidney risk, the newer classes (GLP-1 RAs and SGLT2 inhibitors) offer benefits that go well beyond blood sugar control, and guidelines increasingly reflect that by recommending them early in treatment rather than as later additions.